AbelZeta_CTIL051 (Non-Small Cell Lung Cancer)

What is the Purpose of this Study?

We are doing this study to find out if the combination of 2 experimental drugs called C-TIL051 and NKTR-255 when they are given along with pembrolizumab is a safe and effective option for non-small cell lung cancer (NSCLC). C-TIL051 is custom-made for each participant from their own tumor tissue. Immune cells are isolated from your tumor tissue, regrown in a lab, and then formulated to be returned to your bloodstream. We want to know if C-TIL051 can help people's immune systems target and destroy cancer cells. NKTR-255 is designed to help C-TIL051 work better.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults ages 18 or older who:

  • Are diagnosed with NSCLC
  • Have not received checkpoint inhibitor therapy
  • Have tumor tissue that can be surgically removed
  • Have never received treatment with a cellular therapy

For more information about who can join this study, please contact the study team at 919-681-6468.

Age Group

What is Involved?

If you choose to join this study, you will:

  • Undergo surgery to collect your tumor tissue to make the study drug
  • Receive lympho-depleting chemotherapy
  • Take the study drugs
  • Have physical exams and blood draws
  • Have imaging scans (CT and/or MRI)
  • Have heart tests (ECG)

Study Details

Full Title
C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer
Principal Investigator
Associate Professor of Medicine
Protocol Number
IRB: PRO00112188
NCT: NCT05676749
Phase I
Enrollment Status